The aim of this study was to determine the expression of ABCG2 and ABCB1 proteins in tumors from patients with PC, and to study the impact of these biomarkers on efficacy and outcome of treatment with GemNab. This evidence concerns the gene ABCB1 and pachyonychia congenita.